Latest Content

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

This supplement was supported by AstraZeneca.

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Mental Health Awareness Month puts a spotlight on the prevalence of mental illness throughout the country, as well as reduces the stigma surrounding it.

Durvalumab plus BCG also marks the first new treatment in over 30 years for high-risk non–muscle-invasive bladder cancer.